The treatment, the first of its kind, was approved by the Food and Drug Administration on Thursday. “Our baby was born deaf, and now he can hear,” said one parent.
Category: Regeneron Pharmaceuticals Inc
-
New Gene Therapy Enables Children With a Rare Form of Deafness to Hear
The New York Times – Business: -
23andMe Customers Did Not Expect Their DNA Data Would Be Sold, Lawsuit Claims
The genetic-testing company, which collected DNA data from users, is for sale in bankruptcy court. Now, 27 states and the District of Columbia oppose selling the data without express consent.
-
23andMe to Be Bought by Regeneron Pharmaceuticals, a Biotech Company, for $256 Million
Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer consumer DNA testing services.